Albert D. Bolles's most recent trade in Sunopta, Inc. was a trade of 2,423 Restricted Stock Units done . Disclosure was reported to the exchange on July 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sunopta, Inc. | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2025 | 2,423 | 20,193 | - | - | Restricted Stock Units | |
| Sunopta, Inc. | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 6.64 per share. | 25 Jul 2025 | 1,810 | 228,178 (0%) | 0% | 6.6 | 12,018 | Common Shares |
| Sunopta, Inc. | Albert D. Bolles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 20,072 | 226,368 (0%) | 0% | - | Common Shares | |
| Sunopta, Inc. | Albert D. Bolles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 20,072 | 0 | - | - | Restricted Stock Units | |
| Sunopta, Inc. | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 17,770 | 17,770 | - | - | Restricted Stock Units | |
| Sunopta, Inc. | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 3.90 per share. | 17 Apr 2025 | 2,186 | 206,296 (0%) | 0% | 3.9 | 8,525 | Common Shares |
| Sunopta, Inc. | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 7.38 per share. | 24 Jan 2025 | 1,360 | 204,110 (0%) | 0% | 7.4 | 10,037 | Common Shares |
| Sunopta, Inc. | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 6.02 per share. | 18 Oct 2024 | 1,629 | 202,750 (0%) | 0% | 6.0 | 9,807 | Common Shares |
| Arcadia Biosciences Inc | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2024 | 10,909 | 13,394 | - | - | Stock Option (Right to Buy) | |
| Sunopta, Inc. | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 5.23 per share. | 26 Jul 2024 | 1,912 | 201,121 (0%) | 0% | 5.2 | 10,000 | Common Shares |
| Sunopta, Inc. | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 20,072 | 20,072 | - | - | Restricted Stock Units | |
| Sunopta, Inc. | Albert D. Bolles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 15,283 | 199,209 (0%) | 0% | - | Common Shares | |
| Sunopta, Inc. | Albert D. Bolles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 15,283 | 0 | - | - | Restricted Stock Units | |
| Sunopta, Inc. | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 5.96 per share. | 19 Apr 2024 | 1,337 | 183,926 (0%) | 0% | 6.0 | 7,969 | Common Shares |
| Sunopta, Inc. | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 6.03 per share. | 26 Jan 2024 | 1,679 | 182,589 (0%) | 0% | 6.0 | 10,124 | Common Shares |
| Sunopta, Inc. | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 3.37 per share. | 20 Oct 2023 | 2,726 | 180,910 (0%) | 0% | 3.4 | 9,187 | Common Shares |
| Sunopta, Inc. | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 6.22 per share. | 28 Jul 2023 | 1,317 | 178,184 (0%) | 0% | 6.2 | 8,192 | Common Shares |
| Sunopta, Inc. | Albert D. Bolles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2023 | 14,018 | 176,867 (0%) | 0% | - | Common Shares | |
| Sunopta, Inc. | Albert D. Bolles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2023 | 14,018 | 0 | - | - | Restricted Stock Units | |
| Arcadia Biosciences Inc | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 937 | 2,485 | - | - | Stock Option (Right to Buy) | |
| Sunopta, Inc. | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2023 | 15,283 | 15,283 | - | - | Restricted Stock Units | |
| Sunopta, Inc. | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 8.14 per share. | 21 Apr 2023 | 1,144 | 162,849 (0%) | 0% | 8.1 | 9,312 | Common Shares |
| Sunopta, Inc. | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 8.21 per share. | 02 Feb 2023 | 1,044 | 161,705 (0%) | 0% | 8.2 | 8,571 | Common Shares |
| Arcadia Biosciences Inc | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 23,620 | 62,018 | - | - | Stock Option (right to buy) | |
| Lifecore Biomedical Inc | Albert D. Bolles | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2022 | 55,000 | 0 | - | - | Common Stock | |
| Lifecore Biomedical Inc | Albert D. Bolles | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 23 May 2022 | 55,000 | 100,152 (0%) | 0% | 9.5 | 519,750 | Common Stock |
| Lifecore Biomedical Inc | Albert D. Bolles | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.45 per share. | 23 May 2022 | 27,269 | 72,883 (0%) | 0% | 9.4 | 257,692 | Common Stock |
| Lifecore Biomedical Inc | Albert D. Bolles | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2021 | 91,763 | 91,763 | - | - | Non-Qualified Stock Option (right to buy) | |
| Lifecore Biomedical Inc | Albert D. Bolles | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2021 | 8,237 | 8,237 | - | - | Incentive Stock Option (right to buy) | |
| Arcadia Biosciences Inc | Albert D. Bolles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 10,935 | 38,398 | - | - | Stock Option (right to buy) | |
| Lifecore Biomedical Inc | Albert D. Bolles | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 10.61 per share. | 14 Apr 2021 | 9,000 | 45,152 (0%) | 0% | 10.6 | 95,490 | Common Stock |
| Lifecore Biomedical Inc | Albert D. Bolles | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 10.98 per share. | 19 Jan 2021 | 10,000 | 36,152 (0%) | 0% | 11.0 | 109,800 | Common Stock |
| Lifecore Biomedical Inc | Albert D. Bolles | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 45,000 | 45,000 | - | - | Performance-Based Restricted Stock Units |